Warp Speed bets $356M to mass manufacture a Merck drug for severe Covid-19
The White House is betting big on a new type of treatment for Covid-19, a drug that results from one late-stage trial suggesting it could drastically improve patients’ odds of recovery from severe disease.
HHS and the Department of Defense announced a $356 million deal to mass manufacture MK-7110, the immune system modifying antibody that Merck acquired in their surprise $425 million buyout of OncoImmune last month. The deal would allow Merck to produce between 60,000 and 100,000 doses of the drug by June 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.